Envista Holdings Corporation reports recurring developments as a global dental products company serving dental professionals through consumables, technologies, equipment and services. Its public updates center on quarterly results, core sales trends, adjusted earnings measures, cash flow, share repurchase activity and management presentations at healthcare conferences.
Company news also covers product and brand activity across DEXIS, Kerr, Nobel Biocare and Ormco, including dental implants, orthodontics, digital imaging, restorative and endodontic solutions. Recent product announcements include Kerr Dental's ZenSeal Pro with ZenSave Tips, reflecting Envista's focus on dental workflow, treatment technology and clinician-facing product commercialization.
Envista (NYSE: NVST) reported Q1 2026 results for the quarter ended April 3, 2026. Sales were $706 million with core sales growth of 9.5%. GAAP net income was $39 million; adjusted EBITDA was $99 million (+25% YoY) and adjusted EPS was $0.36 (+50% YoY).
Operating cash flow was negative $3 million and free cash flow was negative $16 million. The Board authorized an incremental $300 million share repurchase program through December 31, 2029. Full‑year 2026 guidance was reaffirmed.
Kerr Dental (NVST) launched ZenSeal Pro with ZenSave Tips on April 16, 2026, a bioceramic sealer system designed to improve delivery efficiency and reduce waste.
The ZenSave Tips cut material waste by 33.5% versus other high-flow BC sealers and enable an average of 57 canals per 1.5 g syringe versus ~48 with comparator systems, with the company estimating over $1,500 in potential annual savings for some practices. ZenSeal Pro is heat compatible, highly flowable, radiopaque, has a pH >11, and supports multiple obturation techniques.
Kerr Dental (NASDAQ:NVST) launched Demi™ Pro on April 16, 2026, a cordless curing light engineered for ergonomics, 360° access, deeper cures, and safety features.
The device highlights a rotatable low-profile tip, integrated radiometer, broad-spectrum output (~380–515 nm), and optional transillumination for chairside assessment.
Envista (NYSE: NVST) will report first quarter 2026 results on Wednesday, May 6, 2026 and will hold a conference call the same day at 2:00 PM PT. The call will last about one hour and will be webcast on the company investor website with slides and a replay available for one year.
Investors can access the call by dialing the provided U.S. and international numbers and referencing Conference ID #51461; presentation materials will be posted to the Investors section before the call.
Envista (NYSE: NVST) reported Q4 2025 and full-year results on Feb 5, 2026. Q4 sales were $751M with 10.8% core sales growth; GAAP diluted EPS was $0.20 and adjusted diluted EPS was $0.38 (+58% YoY). Adjusted EBITDA was $111M (+22% YoY) with a 14.8% margin (+90 bps).
FY 2025 sales were $2,719M with 6.5% core growth, adjusted diluted EPS $1.19 (+63% YoY), adjusted EBITDA $372M (+26% YoY), and free cash conversion 114%. Share repurchases totaled $166M in 2025. 2026 guidance: core sales growth 2–4%, adjusted EBITDA growth 7–13%, adjusted diluted EPS $1.35–$1.45.
Envista (NYSE: NVST) will report fourth quarter 2025 financial results on Thursday, February 5, 2026. A conference call to discuss results will begin at 2:00 PM PT and run about one hour.
The call and accompanying slide presentation will be webcast on the company Investors website (www.envistaco.com). A replay of the webcast will be available shortly after the presentation and will remain available for one year. Dial-in numbers: 1-800-836-8184 (U.S.) or 1-646-357-8785 (outside U.S.) and reference Conference ID #54406. Earnings release, slides, and presentation materials will be posted to the Investors site prior to the call and remain available after the call.
Envista (NYSE: NVST) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 from 3:45–4:25 pm PST. A live audio webcast will be available in the Investors section of Envista's website and a replay will be posted for 30 days following the presentation.
Envista (NYSE: NVST) will participate in the 8th Annual Evercore Healthcare Conference. The company's fireside chat is scheduled for Wednesday, December 3, 2025, from 12:30–1:15 pm ET. A live audio webcast and archived replay will be available in the Investors section of Envista's website at https://investors.envistaco.com/.
This presentation offers investors direct access to management commentary and a replay for later review.
Envista (NYSE: NVST) reported results for the quarter ended September 26, 2025, with Q3 sales of $670 million and core sales growth of 9.4% versus Q3 2024. Adjusted results showed adjusted EPS of $0.32 (+167% year‑over‑year) and adjusted EBITDA of $97 million (+77% year‑over‑year) with an adjusted EBITDA margin of 14.5% (+540 bps). GAAP results included a Q3 net loss of $30 million and GAAP EPS of ($0.18) driven by a tax charge from restructuring intercompany loans. Q3 YTD sales were $1,969 million with adjusted EPS $0.82 and adjusted EBITDA $260 million. Operating cash flow was $79 million and free cash flow $68 million in Q3. The company repurchased 2.1 million shares for ~$41 million and updated full‑year 2025 guidance, raising adjusted EPS to $1.10–$1.15.
Envista (NYSE: NVST) released its 2024 Sustainability Report on October 29, 2025, outlining progress on environmental, social and governance priorities.
Selected highlights include a $1.9 million donation in goods and services via the Envista Smile Project to expand access to oral care, completion of an inaugural Scope 3 GHG emissions inventory, a 13% reduction in the company’s safety incident rate, and strong employee participation and engagement scores. The report summarizes current sustainability performance and identifies areas for continuous improvement. Stakeholder feedback can be sent to sustainability@envistaco.com.